Voyager Therapeutics Reports Q1 2026 Financial Results with Decreased Collaboration Revenue

Voyager Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $2.6 million, a significant decrease from $6.5 million in the same period last year. The decline in revenue is attributed to reduced collaboration activities, particularly under its agreements with Neurocrine and Novartis. The company incurred an operating loss of $30.3 million, an improvement from the $34.7 million loss reported in the first quarter of 2025. The net loss for the quarter was $27.9 million, compared to a net loss of $31.0 million in the prior year, reflecting a decrease in operating expenses.

Total operating expenses for the quarter were $32.9 million, down from $41.2 million in the first quarter of 2025. This reduction was primarily driven by a decrease in research and development expenses, which fell to $24.6 million from $31.5 million, largely due to the discontinuation of the SOD1 program and lower spending on the anti-tau antibody program, VY7523. General and administrative expenses also decreased to $8.3 million from $9.6 million, reflecting cost-cutting measures and a reduction in legal fees.

As of March 31, 2026, Voyager Therapeutics had total assets of $219.3 million, down from $252.3 million at the end of 2025. The company’s cash and cash equivalents decreased to $43.3 million from $65.3 million, while marketable securities also saw a decline. The total liabilities decreased to $45.7 million from $56.2 million, with current liabilities dropping significantly from $26.5 million to $17.5 million, indicating improved management of operational costs.

In terms of strategic developments, Voyager Therapeutics is advancing its proprietary pipeline, which includes programs targeting Alzheimer’s disease and other neurological conditions. The company is preparing to initiate a clinical trial for its tau silencing gene therapy, VY1706, in the second half of 2026, following successful preclinical studies. Additionally, the company has maintained its collaborations with Neurocrine and Novartis, which have provided over $500 million in non-dilutive funding to date.

Looking ahead, Voyager Therapeutics expects its existing cash and marketable securities to be sufficient to meet its operational needs for at least the next twelve months. However, the company acknowledges the need for additional financing to support ongoing research and development activities, including clinical trials and potential commercialization efforts. The management remains cautious about the future, emphasizing the importance of securing further funding to continue its operations and achieve its strategic goals.